The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Sentinel Node Extended in Squamous Cell Vulvar Cancer
Official Title: Can the Investigators Extend the Indication for Sentinel Node Biopsy in Vulvar Cancer? A Nationwide Feasibility Study From Sweden
Study ID: NCT04147780
Brief Summary: The aim of this study is to investigate the feasibility of sentinel node biopsy in patients with squamous cell vulvar cancer, currently not regarded suitable for the sentinel node technique, i.e. patients with tumors ≥4cm, multifocal tumors or locally recurrent disease. A positive result of this pilot study might constitute the basis for a future full-scale multinational trial.
Detailed Description: PRIMARY OBJECTIVES: This study is primarily a pilot and feasibility trial, aiming to evaluate if sentinel node biopsy has a satisfactory detection rate and negative predictive value in certain groups of vulvar cancer patients. OUTLINE: The study is planned as a prospective, multi-center cohort study in Sweden. Since 2017, the treatment of vulvar cancer patients has been accredited to four tertiary referral university hospitals in Sweden; the Sahlgrenska University hospital in Gothenburg, the Linköping University hospital, the Skåne University hospital in Lund and the Karolinska University hospital in Stockholm. Eligible patients will undergo a sentinel node biopsy additionally to their radical inguinofemoral lymphadenectomy and detection rate and negative predictive value for the sentinel procedure will be calculated. The study will consist of four patient groups: Patients with squamous cell vulvar cancer and: 1. primary tumors ≥4cm 2. primary multifocal tumors 3. local recurrence, earlier no treatment of the groins or only sentinel node biopsy 4. local recurrence, earlier treatment of the groins with radiotherapy / inguinofemoral lymphadenectomy It is estimated to include 20-30 patients in each study group during a time frame of about 24 months. RESULTS: Results are to be expected in the end of 2021.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Karolinska University Hospital, Stockholm, Stockholms Lan, Sweden
Sahlgrenska University Hospital, Gothenburg, , Sweden
Linkopings University Hospital, Linkoping, , Sweden
Skanes University Hospital Lund, Lund, , Sweden
Name: Diana Zach, MD
Affiliation: Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
Role: PRINCIPAL_INVESTIGATOR